6 Meridian’s Tvardi Therapeutics TVRD Stock Holding History

6 Meridian’s Portfolio TVRD Stock Details TVRD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-445	Closed	-$229K	–	512
2021 Q2	$229K	Buy	+445	New	+$282K	0.02%	293

Other funds holding TVRD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

DGI

Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

6 Meridian's TVRD Position: Q3 2021 in Review

6 Meridian sold out of Tvardi Therapeutics (TVRD) in Q3 2021, closing a stake of 445 shares — an estimated $229K sold.

6 Meridian first reported a position in TVRD in Q2 2021 and held it in 1 quarter. The position peaked at $229K in Q2 2021. 169 funds tracked by Wall St. Rank hold TVRD as of Q3 2021.

6 Meridian reported no remaining Tvardi Therapeutics position as of Q3 2021 after selling out during the quarter.
6 Meridian sold 445 Tvardi Therapeutics shares in Q3 2021, an estimated $229K.
6 Meridian first reported a position in Tvardi Therapeutics in Q2 2021 and held it in 1 quarter.
6 Meridian's Tvardi Therapeutics position peaked at $229K in Q2 2021.
169 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q3 2021.

Based on 6 Meridian's 13F filing for Q3 2021, filed 3 Nov 2021.